ProfileGDS5678 / 1458252_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 62% 63% 62% 62% 62% 65% 65% 62% 62% 62% 62% 62% 62% 62% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 13.7473962
GSM967853U87-EV human glioblastoma xenograft - Control 23.7352363
GSM967854U87-EV human glioblastoma xenograft - Control 33.7141962
GSM967855U87-EV human glioblastoma xenograft - Control 43.6525562
GSM967856U87-EV human glioblastoma xenograft - Control 53.6347562
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 13.9774365
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 23.9470265
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 33.7150562
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 43.7194562
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 13.7224662
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 23.7190762
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 33.6866862
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 43.7233262
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 53.7252362